A proprietary, CDASH/SDTM-hybrid data model to expedite clinical data review

M.A. Prodhomme¹, L. Gijsbers², T. Van der Spiegel¹

¹Janssen R&D, Beerse, Belgium; ²OCS Life Sciences, 's-Hertogenbosch, the Netherlands

Abstract

In 2016 Janssen identified the need to expedite clinical data review. A proof of concept demonstrated the value of pursuing a new and proprietary data model for data review, serving as single source of truth. The Data Review Model (DRM) that was introduced is strongly based on CDISC SDTM and CDASH. DRM provides full traceability and describes both clinical and operational (system) data consistently across studies. On the longer term, Janssen plans to implement a metadata-driven environment, including data conversion from source data into DRM.

In 2017, OCS Life Sciences and Janssen piloted DRM by implementing a mapping framework that supports both documentation and execution of source to target data mapping. This poster will describe how multiple trials were mapped to support the pilot phase of DRM, to learn, refine and document the value of DRM prior to moving to production implementation [1].

Introduction

At Janssen, Data Management (DM) activities are outsourced to DM CROs:

- Delivering SDTM datasets to Janssen during trial conduct
- Preparing the SDTM Submission Package after Database Lock.

Janssen DM performs ongoing Quality Control on these SDTM deliverables.

In 2016, spending time evaluating the current data flow, Janssen identified the need to expedite clinical data review. The idea of a new data model was introduced, serving as single source of the truth to all consumers of clinical data. What followed was a proof of concept (POC), showcasing 5 newly designed domains. The Data Review Model, in its very early stages, was born. As part of the POC we tried out several use cases:

- How can we most logically cluster/group information in DRM?
- Avoiding the use of SUPPQUAL and Findings About datatypes.
 How to represent relationships in DRM, without the need for RELREC?
- Can we add value by adding new data (variables or datasets) in DRM?
- How will DRM help when mapping a new exploratory data stream?
- Will DRM allow an easy transformation to SDTM?



Conclusion

To improve the data flow, following a successful proof of concept and pilot phase, Janssen is introducing a new data model to help expedite access to data and facilitate data review operations.

This Data Review Model provides a general framework for describing clinical trial and operational data in a rather simple, well-structured and consistent/uniform way.

It provides clear traceability to the collected source data, it positively impacts the review of data and it allows an easy and controlled transformation to SDTM.

References

- 1. Lieke Gijsbers, OCS Life Sciences, 's-Hertogenbosch, the Netherlands, Tom Van der Spiegel, Janssen R&D, Beerse, Belgium, A proprietary, CDASH/SDTM-hybrid data model to expedite clinical data review, PhUSE 2018, Paper SI25
- Bas van Bakel, OCS Consulting, 's-Hertogenbosch, the Netherlands, DIY: Create your own SDTM mapping framework, PhUSE 2016, Paper CD03

DRM Mapping Specification



All source-to-target specifications

- Translation of specifications into code or pseudo-code.
- Recode table
- Data sets order

DRM Metadata



Order of DRM variables The attributes of the DRM variables

• Key variables for the sorting of records





